Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Generic Sterile Injectables Market 

5.1. COVID-19 Landscape: US Generic Sterile Injectables Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Generic Sterile Injectables Market, By Product Type

8.1. US Generic Sterile Injectables Market Revenue and Volume, by Product Type, 2024-2033

8.1.1 Monoclonal Antibodies

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Cytokines

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Insulin

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Peptide Hormones

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Vaccines

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Immunoglobulin

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Blood Factors

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Antibiotics

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Others

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. US Generic Sterile Injectables Market, By Therapeutic Application

9.1. US Generic Sterile Injectables Market Revenue and Volume, by Therapeutic Application, 2024-2033

9.1.1. Cancer

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Diabetes Therapeutic Application

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Cardiovascular Disease

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Central Nervous System

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Musculoskeletal System

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Others

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. US Generic Sterile Injectables Market, By Distribution Channel 

10.1. US Generic Sterile Injectables Market Revenue and Volume, by Distribution Channel, 2024-2033

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Drug Stores

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Retail Pharmacies

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. US Generic Sterile Injectables Market, and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Volume Forecast, by Product Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Therapeutic Application (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. Pfizer

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Mylan

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sandoz

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. 3M

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Par Pharmaceutical, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Hikma Pharmaceuticals PLC

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Gland Pharma Limited

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. CIVICA

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Ascendia Pharmaceuticals

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Merck & Co., Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms